- Home
- AAM vs ATAI Comparison
AAM vs ATAI Comparison
Compare AAM & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AAM
- ATAI
- Stock Information
- Founded
- AAM 2024
- ATAI 2018
- Country
- AAM United States
- ATAI Germany
- Employees
- AAM N/A
- ATAI N/A
- Industry
- AAM
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- AAM
- ATAI Health Care
- Exchange
- AAM Nasdaq
- ATAI Nasdaq
- Market Cap
- AAM 460.0M
- ATAI 444.7M
- IPO Year
- AAM 2024
- ATAI 2021
- Fundamental
- Price
- AAM $10.50
- ATAI $4.85
- Analyst Decision
- AAM
- ATAI Strong Buy
- Analyst Count
- AAM 0
- ATAI 3
- Target Price
- AAM N/A
- ATAI $13.33
- AVG Volume (30 Days)
- AAM 14.5K
- ATAI 4.7M
- Earning Date
- AAM 01-01-0001
- ATAI 11-12-2025
- Dividend Yield
- AAM N/A
- ATAI N/A
- EPS Growth
- AAM N/A
- ATAI N/A
- EPS
- AAM 0.32
- ATAI N/A
- Revenue
- AAM N/A
- ATAI $2,309,000.00
- Revenue This Year
- AAM N/A
- ATAI $712.99
- Revenue Next Year
- AAM N/A
- ATAI N/A
- P/E Ratio
- AAM $32.62
- ATAI N/A
- Revenue Growth
- AAM N/A
- ATAI 510.85
- 52 Week Low
- AAM $9.98
- ATAI $1.03
- 52 Week High
- AAM $10.79
- ATAI $5.34
- Technical
- Relative Strength Index (RSI)
- AAM 55.61
- ATAI 64.59
- Support Level
- AAM $10.48
- ATAI $4.50
- Resistance Level
- AAM $10.51
- ATAI $4.75
- Average True Range (ATR)
- AAM 0.01
- ATAI 0.28
- MACD
- AAM 0.00
- ATAI -0.03
- Stochastic Oscillator
- AAM 85.71
- ATAI 76.02
About AAM AA Mission Acquisition Corp. Class A Ordinary Shares
AA Mission Acquisition Corp is a blank check company.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.